Physician profile
Jan Master
NPI 1437134434
$2,492.71
in general payments reported to CMS, 2019-2025
27 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $484 · 2022: $745 · 2023: $489 · 2024: $533 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.56 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $447.30 | 2022-2025 | Veozah |
| Organon LLC | $352.62 | 2021-2025 | Nexplanon, Nuvaring |
| Abbvie INC. | $312.60 | 2021-2023 | |
| Therapeuticsmd, INC. | $219.09 | 2021-2022 | |
| Inspire Medical Systems, INC. | $127.41 | 2024 | Inspire |
| Mayne Pharma Commercial LLC | $119.28 | 2022-2025 | |
| Renovia INC | $104.03 | 2021 | |
| Phathom Pharmaceuticals, INC. | $90.87 | 2024 | Voquezna |
| Pfizer INC. | $78.88 | 2021-2024 | |
| Exact Sciences Corporation | $69.60 | 2023-2024 | Cologuard Collection Kit |
| Myovant Sciences INC. | $69.31 | 2022 | |
| Merck Sharp & Dohme LLC | $64.85 | 2021-2023 | Gardasil 9 |
| Coopersurgical, INC. | $61.09 | 2021-2024 | Paragard T 380a |
| Evofem Biosciences, INC. | $56.40 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.83 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $33.54 | 2023 | Myrisk |
| Avion Pharmaceuticals | $32.83 | 2021-2022 | |
| Scynexis, INC. | $32.05 | 2022 | |
| Shield Therapeutics INC | $28.97 | 2025 | |
| Sumitomo Pharma America, INC. | $23.00 | 2024 | Myfembree |
| Hologic Sales and Service, LLC | $22.81 | 2023 | Aptima |
| Seqirus USA INC | $18.38 | 2024 | Flucelvax |
| Amgen INC. | $18.37 | 2021 | |
| Aspira Women'S Health INC | $17.94 | 2023 | Ova1 |
| Exeltis, USA INC. | $16.70 | 2024 | Slynd |
| Agile Therapeutics, INC. | $15.97 | 2021 | |
| Sage Therapeutics, LLC | $13.99 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Master listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.